Literature DB >> 16604330

[Organ-preserving treatment in inoperable patients with primary oral and oropharyngeal carcinoma: chances and limitations].

A F Kovács1, K Eberlein, A Smolarz, S Weidauer, S Rohde.   

Abstract

INTRODUCTION: The aim of this study was to demonstrate the chances of nonoperative therapy in those patients from an unselected population suffering from primary previously untreated squamous cell carcinomas of the oral cavity and the oropharynx who did not seem to be operable. PATIENTS AND METHODS: Following interdisciplinary counseling and extensive individual discussion, 72 (21%) of 340 consecutive patients (1997-2004) did not or did not reasonably seem to be operable; three other patients with stage II disease refused surgery. Of the inoperable patients, 95%suffered from far-advanced stage IV disease, 8% had distant metastases, 14% had synchronous malignancies, 9% were aged over 85 years combined with advanced malignant disease, and nearly 50% were limited in their activity or were even bedridden. Depending on fitness and tumor extent, three therapy regimens were used: intra-arterial (i.a.) high-dose chemotherapy with systemic antagonization for palliation, induction with this i.a. high-dose chemotherapy followed by additional radiotherapy, and induction with the i.a. high-dose chemotherapy followed by additional radiochemotherapy.
RESULTS: Thirty-two patients were treated with i.a. chemotherapy alone for palliation with few acute side effects. The response rate was 34%, and a further growth of the tumour could be inhibited in 49%. The 1- and 2-year survival rates were 21 and 14%, respectively. The three patients who refused surgery experienced complete clinical remission and survived 8, 6, and 2 years, respectively, to date. Twenty-three patients were fit enough to receive additional radiotherapy, and 17 an additional radiochemotherapy. Of the patients, 22% had to cut short additional radiotherapy and 47% had to discontinue concomitant chemotherapy. The 1- and 2-year survival rates were 41 and 25%, respectively; 14 of these irradiated patients experienced long-lasting complete clinical remission >2 years.
CONCLUSION: About 20% of the patients classified as inoperable could achieve long-lasting remission. Viewed with caution, sex (male), performance state (ECOG) <3, and positive response to i.a. chemotherapy could be regarded as predictors for therapeutic success. The combination of i.a. chemotherapy and radiochemotherapy seemed to be most successful. Conversely, the therapies offered could not achieve a substantial improvement of survival in 80% of patients classified as inoperable; the most successful therapy combination could be offered to merely 23% of patients as classified inoperable due to reduced general condition. The i.a. high-dose chemotherapy has to be regarded as a well tolerated and effective palliation. This descriptive analysis must be followed by specific studies to establish clinical treatment recommendations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604330     DOI: 10.1007/s10006-006-0684-2

Source DB:  PubMed          Journal:  Mund Kiefer Gesichtschir        ISSN: 1432-9417


  16 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.

Authors:  Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson
Journal:  N Engl J Med       Date:  1991-06-13       Impact factor: 91.245

3.  Treatment of lower lip cancer: an experience of 48 cases.

Authors:  A C Salgarelli; F Sartorelli; A Cangiano; M Collini
Journal:  Int J Oral Maxillofac Surg       Date:  2005-01       Impact factor: 2.789

4.  Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

Authors:  T G Wendt; G G Grabenbauer; C M Rödel; H J Thiel; H Aydin; R Rohloff; T P Wustrow; H Iro; C Popella; A Schalhorn
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

5.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

6.  Sentinel node biopsy as staging tool in a multimodality treatment approach to cancer of the oral cavity and the oropharynx.

Authors:  Adorján F Kovács; Constantin A Landes; Nadja Hamscho; Jörn H Risse; Uwe Berner; Christian Menzel
Journal:  Otolaryngol Head Neck Surg       Date:  2005-04       Impact factor: 3.497

7.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

8.  Maximized combined modality treatment of an unselected population of oral and oropharyngeal cancer patients. Final results of a pilot study compared with a treatment-dependent prognosis index.

Authors:  Adorján F Kovács
Journal:  J Craniomaxillofac Surg       Date:  2006-01-19       Impact factor: 2.078

9.  Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients.

Authors:  K T Robbins; P Kumar; F S Wong; W F Hartsell; P Flick; R Palmer; A B Weir; H B Neill; T Murry; R Ferguson; C Hanchett; F Vieira; A Bush; S B Howell
Journal:  Head Neck       Date:  2000-10       Impact factor: 3.147

10.  Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.

Authors:  Adorján F Kovács; Mirko Schiemann; Bernd Turowski
Journal:  J Craniomaxillofac Surg       Date:  2002-04       Impact factor: 2.078

View more
  2 in total

1.  [Survival improvement of a unicentric overall population in 20 years: 1038 patients with oral and oropharyngeal squamous cell cancer 1983-2004].

Authors:  Adorján F Kovács; Waleed Megahed; Michael Scholz; Robert Sader
Journal:  Mund Kiefer Gesichtschir       Date:  2007-09-25

2.  Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.

Authors:  Adorján F Kovács; Klaus Eberlein; Tina Hülsmann
Journal:  Oral Maxillofac Surg       Date:  2009-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.